# Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer

> **NCT00871169** · PHASE2 · COMPLETED · sponsor: **New Mexico Cancer Research Alliance** · enrollment: 61 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Irinotecan, oxaliplatin, and cetuximab

## Key facts

- **NCT ID:** NCT00871169
- **Lead sponsor:** New Mexico Cancer Research Alliance
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2016-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00871169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00871169, "Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT00871169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*